Busy modern lives coupled with the inconvenience of in-person visits to a clinician’s office make it hard for us to prioritize early heart disease risk screening for timely prevention
Current lipid-based risk screening tests are not as effective as physicians would like, with an average sensitivity rate of only 44% in men and 35% in women
With the overwhelming amount of information around heart disease risk screening, taking your first step towards prevention can be stressful
Request the test, collect your sample, and consult with a telemedicine clinician - all from the comfort of your home
Epi+Gen CHD™ sensitively measures your personal inherited and acquired risk of having a heart attack within three years
This test is performed in a CLIA certified lab under the supervision of our board-certified medical director
Control access to your data; Decide how it can be used and with whom it can be shared
Determine risk for disease well in advance of an acute event such as a heart attack or stroke.
Work with your physician to establish a prevention roadmap that is tailored to your risk profile.
Follow up testing allows you to understand how your risk has changed over time. Your physician may use this information to modify your treatment plan.
Cardio Diagnostics’ vision is to transform the approach to heart disease from treatment-based to prevention-based. We believe that prevention and early detection should be the norm, and that epigenetics-based technologies driven by artificial intelligence will unlock a new era of precision cardiovascular medicine that can help save lives and significantly cut unnecessary treatment costs.
Our team is made up of subject matter experts with deep expertise in cardiovascular disease prevention, clinical testing, artificial intelligence, and engineering. We also have personal experience with heart disease and want to help you and your loved ones avoid its devastating impact.
Filter out the noise and empower yourself with knowledge to be in
control of your heart health with our monthly newsletter.